SELLAS Life Sciences (SLS) Operating Income (2011 - 2026)
SELLAS Life Sciences' (SLS) quarterly Operating Income came in at -$9.3 million in Q1 2026, down 52.6% year-on-year from -$19.5 million in Q1 2025, and down 12.08% on a QoQ basis from -$8.3 million in Q4 2025.
SELLAS Life Sciences (SLS) Operating Income (2011 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has 14 years of Operating Income data on file, last reported at -$9.3 million in Q1 2026.
- On a quarterly basis, Operating Income fell 52.6% year-over-year to -$9.3 million in Q1 2026; TTM through Mar 2026 was -$31.5 million, a 12.65% decrease from a year earlier, with the FY2025 full-year figure at -$28.3 million, up 10.28% from the prior year.
- Operating Income for Q1 2026 stood at -$9.3 million, down from -$8.3 million in the prior quarter.
- Over the last five years, Operating Income for SLS reached as high as -$6.1 million in Q1 2025 and fell as low as -$16.7 million in Q1 2022.
- Historically, Operating Income has averaged -$8.8 million across 5 years, with a median of -$8.3 million in 2025.
- Across the five-year window, Operating Income sank 645.43% in 2022 and soared 37.14% in 2025, its largest moves.
- Year by year, Operating Income stood at -$9.4 million in 2022, then advanced by 13.43% to -$8.2 million in 2023, then grew by 15.4% to -$6.9 million in 2024, then declined by 19.33% to -$8.3 million in 2025, then retreated by 12.08% to -$9.3 million in 2026.
- Per Business Quant data, the three most recent Operating Income figures were -$9.3 million in Q1 2026, -$8.3 million in Q4 2025, and -$7.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | SELLAS Life Sciences | 3.23 Mn | 3.23 Mn | - | -9.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.25 Mn |
| Dec 31, 2025 | -8.26 Mn |
| Sep 30, 2025 | -7.08 Mn |
| Jun 30, 2025 | -6.87 Mn |
| Mar 31, 2025 | -6.06 Mn |
| Dec 31, 2024 | -6.92 Mn |
| Sep 30, 2024 | -7.33 Mn |
| Jun 30, 2024 | -7.62 Mn |
| Mar 31, 2024 | -9.65 Mn |
| Dec 31, 2023 | -8.18 Mn |
| Sep 30, 2023 | -9.36 Mn |
| Jun 30, 2023 | -9.05 Mn |
| Mar 31, 2023 | -11.28 Mn |
| Dec 31, 2022 | -9.45 Mn |
| Sep 30, 2022 | -7.15 Mn |
| Jun 30, 2022 | -8.62 Mn |
| Mar 31, 2022 | -16.74 Mn |
| Dec 31, 2021 | -11.62 Mn |
| Sep 30, 2021 | -6.98 Mn |
| Jun 30, 2021 | -4.45 Mn |